Author Correction to: CNS Drugs 10.1007/s40263-018-0498-4
An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 March 2018. An error was subsequently identified in the article, and the following correction should be noted:
Table 2, Primary efficacy results for the phase III studies and pooled populations at week 12: in the ‘Pooled’ section of the table, the ‘Placebo’ and ‘ADS-5102’ column headings are transposed. The corrected table is shown in the following page.
The original article has been corrected.
Table 2.
Primary efficacy results for the phase III studies and pooled populations at week 12
| Parameter | EASE LID | EASE LID 3 | Pooled | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LS mean change from baseline (SE) | LS mean change from baseline (SE) | LS mean change from baseline (SE) | ||||||||||
| ADS-5102 [n = 63] | Placebo [n = 58] | Treatment differencea [95% CI] | p valueb | ADS-5102 [n = 37] | Placebo [n = 38] | Treatment differencea [95% CI] | p valueb | ADS-5102 [n = 100] | Placebo [n = 96] | Treatment differencea [95% CI] | p valueb | |
| UDysRS total score, absolute | − 15.9 (1.6) | − 8.0 (1.6) | − 7.9 (− 12.5, − 3.3) | 0.0009 | − 20.7 (2.2) | − 6.3 (2.1) | − 14.4 (− 20.4, − 8.3) | < 0.0001 | − 17.7 (1.3) | − 7.6 (1.3) | − 10.1 (− 13.8, − 6.5) | < 0.0001 |
| UDysRS total score, relative, % | − 37.0 (5.8) | − 11.6 (5.9) | − 25.4 (− 41.7, − 9.0) | 0.0027 | − 45.8 (5.2) | − 16.3 (4.9) | − 29.6 (− 43.9, − 15.3) | < 0.0001 | − 41.1 (4.2) | − 13.9 (4.1) | − 27.3 (− 38.7, − 15.8) | < 0.0001 |
| UDysRS historical score (Parts I and II) | − 9.9 (1.0) | − 5.4 (1.0) | − 4.5 (− 7.4, − 1.6) | 0.0027 | − 12.1 (1.5) | − 4.0 (1.4) | − 8.1 (− 12.1, − 4.1) | 0.0001 | − 10.7 (0.86) | − 5.1 (0.84) | − 5.6 (− 8.0, − 3.3) | < 0.0001 |
|
UDysRS objective score (Parts III and IV) |
− 6.1 (0.9) | − 2.7 (1.0) | − 3.4 (− 6.1, − 0.8) | 0.0120 | − 8.7 (1.3) | − 2.2 (1.2) | − 6.5 (− 10.1, − 3.0) | 0.0004 | − 7.0 (0.76) | − 2.5 (0.75) | − 4.5 (− 6.6, − 2.4) | < 0.0001 |
CI confidence interval, LS least squares, SE standard error, UDysRS Unified Dyskinesia Rating Scale
aADS-5102–placebo
bP values are based on the comparison of ADS-5102 versus placebo from the mixed effect model repeat measurement model